What is ZNTL's market cap?

$166.62M, based on the Nov 4 close of $1.76.

Does Zentalis Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ZNTL is sold short?

6.0M shares, 9.1% of float, as of Oct 15, 2026.

What sector is ZNTL in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ZNTLHealthcarePharmaceuticals

Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL)

$1.76−1.12%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$1.78▲ 23.61% in range

Nov 3, 2025Low $1.28 · High $6.61Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Zentalis Pharmaceuticals closed at $1.76 on Nov 4, down 1.12%, 73.4% below its 52-week closing high. Volume of 1.1M shares was 0.89× its 20-day average (close to normal).

Split-adjusted performance: -34.1% over one month, -57.9% over six months, +22.2% over one year.

Short interest was 6.0M shares at the Oct 15 settlement (9.1% of float, 4.8 days to cover).

Market cap$166.6M94.7M shares

Revenue · quarter$0.00—

Diluted EPS$-0.59—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.28 – 6.61−73.4% from high

Volume1.1M0.89× 20-day avg

Volatility · 60d71.0%Annualised

Short % of float9.1%4.8 days to cover

Net cash$174.6MCash $174.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −14.6%1M −34.1%3M −64.8%6M −57.9%YTD +30.4%1Y +22.2%3Y −89.0%5Y −97.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum19

Revenue growth—

Net margin—

Value (low P/E)—

Size45

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short6.0M+0.5% vs prior

Days to cover4.8Settled Oct 15

% of float9.1%

Short vol. 10d49.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ZNTLZentalis Pharmaceuticals	$1.76	−1.12%	−57.9%	—	—	—	$166.6M
INOInovio Pharmaceuticals	$1.62	−2.41%	+30.6%	—	—	—	$167.5M	Compare
SIONSionna Therapeutics	$3.73	+2.19%	−91.4%	—	—	—	$168.6M	Compare
PEPGPepGen	$2.45	−0.41%	+32.8%	—	—	—	$169.7M	Compare
ORMPOramed Pharmaceuticals	$4.13	+3.25%	+5.4%	—	—	1.0	$171.8M	Compare
ANTXAN2 Therapeutics	$4.25	+1.67%	−8.6%	—	—	—	$160.4M	Compare
WHWKWhitehawk Therapeutics	$3.17	+2.26%	−23.6%	—	—	—	$180.7M	Compare
BBOTBridgeBio Oncology Therapeutics	$2.30	−0.86%	−72.4%	—	—	—	$184.4M	Compare
RNAAtrium Therapeutics	$8.68	−0.46%	−33.7%	−21.9%	−672.0%	—	$148.5M	Compare

News about Zentalis Pharmaceuticals

All news →

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · 2d agoNeutral Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 AbstractGlobeNewswire Inc. · Oct 18, 2026▲ Positive Osteosarcoma Therapeutics Pipeline 2026: Explore 25+ Companies and 32+ Pipeline DrugsGlobeNewswire Inc. · Jul 3, 2026Neutral Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 1, 2026Neutral

Quick answers

What does Zentalis Pharmaceuticals do?: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
What is ZNTL's market cap?: $166.62M, based on the Nov 4 close of $1.76.
Does Zentalis Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ZNTL is sold short?: 6.0M shares, 9.1% of float, as of Oct 15, 2026.
What sector is ZNTL in?: Healthcare, in the Pharmaceuticals industry.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

HQ: San Diego, CA106 employeesListed Apr 3, 2020zentalis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology